In the assessment of 12-month price targets, analysts unveil insights for Sangamo Therapeutics, presenting an average target ...
Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following ...
Sangamo (SGMO) delivered earnings and revenue surprises of -22.22% and 52.51%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The company said, “2025 operating expenses on a non-GAAP basis are expected to be roughly in line with 2024, reflecting our intention to ...
Pre-earnings options volume in Sangamo (SGMO) is normal with calls leading puts 15:1. Implied volatility suggests the market is anticipating a ...
The average 12 month price objective among brokers that have issued a report on the stock in the last year is $5.80. Several equities research analysts have recently weighed in on SGMO shares.
Sangamo posted a Q4 loss of $0.11 per share, $0.01 worse than the $0.10 loss analysts had forecast. Revenue for the quarter came in at $7.55 million, missing the consensus estimate of $10.32 million.
Sangamo Therapeutics Inc. SGMO) on Monday reported a loss of $23.4 million in its fourth quarter.
Today, several major companies are expected to report earnings: CBAK Energy Technology (CBAT), Sangamo Biosciences (SGMO), ...
SANGAMO THERAPEUTICS ($SGMO) is expected to release its quarterly earnings data on Monday, March 17th after market close, per Finnhub. Analysts are expecting revenue ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...